The trial ran for a little over a year and showed an average decrease in BMI of 16% (compared to 0.6% for placebo)
In a major clinical trial, people taking the highest dose lost about 11% of their body weight over 72 weeks
It is a recombinant form of the peptide exendin-4, which is a GLP-1 receptor agonist with a 53% similarity to the gastrointestinal hormone GLP-1 and it is resistant to DPP-4 inactivation with a 140-minute half-life after subcutaneous administration allowing therapy by a twice daily administration [36]
Fortunately, a fentanyl screen is a simple, inexpensive test that shows the supplier takes safety seriously
As energy homeostasis involves innumerous interactions among redundant neural mechanisms 3,4,5 , it is reasonable to consider that treating a complex disease such as obesity may require combinatorial therapies that target multiple energy balance-regulating pathways
Copper transport and cellular regulation. Am J Clin Nutr